Phase Ia of Pfs25-IMX313/Matrix-M1 in healthy adults living in the UK (VAC077)

This Phase 1a clinical trial is designed primarily to assess the safety and tolerability of the Pfs25-IMX313/Matrix-M transmission blocking vaccine in healthy adult volunteers. An important secondary objective is to assess the immune response to the vaccine. 8 volunteers will receive 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56. Blood samples will be taken for safety testing and to collect information about the immune response. Any symptoms that occur after vaccination will also be recorded. Healthy volunteers aged 18-45 will be recruited in England at the Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford.

Study type: Interventional
Enrollment: 1 participant
Primary purpose: Prevention
Interventional Model: Single group assignment
Masking: Open label
NCT number: NCT04130282
Phase: Phase I

Clinical trial registration

Vaccines

Sep 2019 — Sep 2020

United Kingdom